论文部分内容阅读
目的:探讨孕三烯酮联合尿促性素对子宫内膜异位患者性激素及受孕率的影响。方法:选取92例子宫内膜异位症(EMS)患者为研究对象,根据随机数字表将患者分为观察组和对照组各46例,对照组给予孕三烯酮治疗,观察组在对照组基础上联合尿促性素治疗,疗程为6个月。对两组患者随访1年,观察两组性激素水平及受孕率。结果:观察组总缓解率为91.30%,对照组总缓解率为71.74%,两组差异有统计学意义(P<0.05)。观察组治疗3、6、12月孕酮(P)、雌二醇(E2)、促卵泡成熟素(FSH)、促黄体生成素(LH)水平显著低于治疗前及对照组同一时期激素水平,差异有统计学意义(P<0.05)。观察组1年妊娠率69.56%显著高于对照组46.48%,复发率低于对照组,差异有统计学意义(P<0.05),两组不良反应差异无统计学意义(P>0.05)。结论:孕三烯酮联合尿促性素治疗子宫内膜异位症可有效改善患者性激素水平,可提高患者受孕率,复发率及并发症率低,安全有效,值得临床应用。
Objective: To investigate the effect of gestrinone combined with urinary gut hormones on sex hormones and pregnancy rate in patients with endometriosis. Methods: Ninety-two patients with endometriosis (EMS) were enrolled in this study. According to the random number table, the patients were divided into observation group (46 cases) and control group (46 cases). The control group was treated with gestrinone. The observation group Based on the combination of urinary hormone therapy, treatment for 6 months. Two groups of patients were followed up for 1 year, observe the two groups of sex hormones and conception rate. Results: The total remission rate was 91.30% in the observation group and 71.74% in the control group, with significant difference between the two groups (P <0.05). The levels of progesterone (P), estradiol (E2), follicle-stimulating hormone (FSH) and luteinizing hormone (LH) in observation group were significantly lower than those in the same period before treatment and in the control group , The difference was statistically significant (P <0.05). The 1-year pregnancy rate in the observation group was 69.56%, significantly higher than that in the control group (46.48%). The recurrence rate was lower in the observation group than in the control group (P <0.05). There was no significant difference in adverse reactions between the two groups (P> 0.05). Conclusion: Gestrinone combined with urinary guttate can effectively improve the level of sex hormone in patients with endometriosis, which can improve the pregnancy rate, recurrence rate and complication rate of patients with low, safe and effective, and worthy of clinical application.